Neoadjuvant chemotherapy for oesophageal cancer: The need for accurate response prediction and evaluation

Surgeon

Volumn 3, Issue 6, 2005, Pages 373-382

  Forshaw, M J ^a   Gossage, J A ^a   Mason, Robert C ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Neoadjuvant; Oesophageal cancer; Response to therapy

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IRINOTECAN; MOLECULAR MARKER; NAVELBINE; OXALIPLATIN; TAXANE DERIVATIVE; VINDESINE;

ACCURACY; ADJUVANT CHEMOTHERAPY; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; EARLY DIAGNOSIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; META ANALYSIS; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RECURRENCE RISK; REVIEW; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 29244463858     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(05)80047-2     Document Type: Review

References (118)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83:18-29.
2. CRC (Cancer Research Campaign). Cancer Stats Mortality -UK. 1999. London: Cancer Research Campaign.
3. CRC (Cancer Research Campaign). Factsheet 1.1 Incidence -UK. 1998. London: Cancer Research Campaign.
4. Pera M, Pera M. Recent changes in the epidemiology of esophageal cancer. Surg Oncol 2001; 10: 81-90.
5. Dolan K, Sutton R, Walker SJ, Morris AI, Campbell F, Williams EM. New classification of oesophageal and gastric carcinoma derived from changing patterns in epidemiology. Br J Cancer 1999; 80: 834-42.
6. Ajani, JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, Abbruzzese JL, Levin B, DeCaro L, Mountain C. Evaluation of pre- and postoperative chemotherapy for respectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1990; 8: 1231-38.
7. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2002; 183: 274-79.
8. Lerut T. Esophageal surgery at the end of the millennium. J Thorac Cardiovasc Surg 1998; 116: 1-20.
9. Allum WH, Griffin SM, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancers. Gut 2002; 50 (Suppl): v1-v23.
10. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for respectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomised clinical trials. Ann Surg Oncol 2003; 10: 754-61.
11. Malthaner R, Fenlon D. Preoperative chemotherapy for resectable esophageal cancer (Cochrane Review). In: The Cochrane Library, 2002, Issue 4. Oxford: Update Software.
12. Stein HJ, Sendler A, Fink U, Siewert JR. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am 2000; 80: 659-82.
13. Entwistle JWC, Goldberg M. Multimodality therapy for resectable cancer of the thoracic esophagus. Ann Thorac Surg 2002; 73:1009-15.
14. Lerut T, Coosemans W, De Leyn P, Van Raemdonck D, Deneffe G, Decker G. Treatment of esophageal carcinoma. Chest 1999; 116 (suppl 6): 463S-465S.
15. Bartels H, Stein HJ, Siewart JR. Preoperative risk analysis and postoperative mortality of oesophagectomy for respectable oesophageal cancer. Br J Surg 1998; 85: 840-44.
16. Harrison LE. Is esophageal cancer a surgical disease? J Surg Oncol 2000; 75: 227-31.
17. Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Van Raemdonck D. Cancer of the esophagus and gastroesophageal junction: potentially curative therapies. Surg Oncol 2001; 10: 113-22.
18. Stein HJ, Feith M, Siewart JR. Cancer of the esophagogastric junction. Surg Oncol 2000; 9: 35-41.
19. Wayman J, Bennett MK, Raimes SA, Griffin SM. The pattern of recurrence of adenocarcinoma of the oesophagogastric junction. Br J Cancer 2002; 86: 1223-29.
20. Malthaner RA, Wong RK, Rumble RB, Zuraw L; Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35.
21. O'Sullivan GC, Sheehan D, Clarke A, Stuart R, Kelly J, Kiely MD, Walsh T, Collins JK, Shanahan F. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology 1999; 116: 543-48.
22. Sutton P, Clark P. Neo-adjuvant treatment for esophageal cancer. GI Cancer 2000; 3: 231-38.
23. Walsh TN, Grannell M, Mansoor S. Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer. J Gastroenterol Hepatol 2002; 17 Suppl: S172-75.
24. Zacherl J, Sendler A, Stein HJ, Ott K, Feith M, Jakesz R, Siewert JR, Fink U. Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus. World J Surg 2003; 27: 1067-74.
25. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004; 91: 540-51.
26. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J et al. Chemotherapy followed by surgery compared with surgery alone for localised esophageal cancer. N Engl J Med 1998; 339: 1979-84.
27. Allum W, Cunningham D, Weeden S on behalf of the National Cancer Research Institute Upper Gastrointestinal Cancer Clinical Study Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer. A randomised controlled trial (the MAGIC trial ISRCTN 93793971). Proc Am Soc Clin Oncol 2003; 21: 998 (abstract).
28. Geh, JI, Glynne-Jones R, Kwok QSK, Banerji U, Livingstone JI, Townsend ER et al. Preoperative ECF chemotherapy in Gastro-Oesophageal Adenocarcinoma. Clin Oncol (R Coll Radiol) 2000; 12: 182-87.
29. Alderson D. Neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2001; 13: 153-54.
30. Archer VR, Mulholland PJ, Stocken DD, Darnton SJ, Ferry DR. Combined results from three Phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2001; 13: 164-69.
31. Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomised trial. J Thorac Cardiovasc Surg 1997; 114: 210-17.
32. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with respectable esophageal squamous cell carcinoma. Cancer 2001; 91: 2165-74.
33. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomised clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988; 96: 242-48.
34. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-65.
35. Office for National Statistics Registrations of cancers diagnosed in 1993-1996, England and Wales. Health Quarterly Journal 1999; 4: 59-70.
36. Department of Health. The NHS Cancer Plan: A plan for investment, a plan for reform. London: The Stationery Office, 2000.
37. Department of Health. Improving outcomes in Upper Gastrointestinal Cancers: Guidance on Commissioning; Cancer services; the Manual. London: Department of Health, 2001.
38. Branagan G, Davies N. Early impact of centralisation of oesophageal cancer surgery services. Br J Surg 2004; 91: 1630-32.
39. Bachmann MO, Alderson D, Edwards D, Wotton S, Bedford C, Peters TJ, Harvey IM. Cohort study in South and West England of the influence of specialisation on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg 2002; 89: 914-22.
40. Dickson GH, Waters R, Bull J, Kaul V, Sitzia J. Should we continue oesophageal surgery in a district general hospital? A review of 200 consecutive cases. Ann R Coll Surg Engl 2001; 83: 167-71.
41. Matthews HR, Powell DJ, McConkey CC. Effect of surgical experience on the results of resection for oesophageal carcinoma. Br J Surg 1986; 73: 621-23.
42. Gillison EW, Powell J, McConkey CC, Spychal RT. Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia. Br J Surg 2002; 89: 344-48.
43. Department of Health. The NHS Cancer Plan and the new NHS: providing a patient-centres service. London: Department of Health, 2004.
44. CRC (Cancer Research Campaign). Factsheet 1.1 Incidence - UK. 1998. London: Cancer Research Campaign, 1998.
45. Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet 1995; 345: 1265-70.
46. Gillis CR, Hole DJ. Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland. BMJ 1996; 312: 145-48.
47. Gillis CR, Hole DJ, Still RM, Davis J, Kaye SB. Medical audit, cancer registration and survival in ovarian cancer. Lancet 1991; 337: 611-12.
48. Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. Br J Cancer 1994; 70: 1014-17.
49. Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, Ajani JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. J Thorac Cardiovasc Surg. 2000; 119: 1126-32.
50. van Lanschot JJ, Hulscher JB, Buskens CJ, Tilanus HW, ten Kate FJ, Obertop H. Hospital volume and hospital mortality for esophagectomy. Cancer. 2001; 91: 1574-78.
51. Allum WH, Griffin SM, Watson A, Colin-Jones D. Guidelines for the management of oesophageal and gastric cancers. Gut 2002; 50 (Suppl): v1-v23.
52. McCulloch P, Ward J, Tekkis PP. Mortality and morbidity in gastro-oesophageal cancer surgery: initiall results of ASCOT multicentre prospective cohort study. BMJ 2003; 327: 1192-97.
53. Bailey SH, Bull DA, Harpole DH, Rentz JJ, Neumayer LA, Pappas TN, Daley J, Henderson WG, Krasnicka B, Khuri SF. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003; 75: 217-22
54. Heitmiller RF, Fischer A, Liddicoat JR. Cervical esophagogastric anastomosis: results following esophagectomy for carcinoma. Dis Esophagus 1999; 12: 264-69.
55. Ellis FH Jr. Treatment of carcinoma of the esophagus or cardia. Mayo Clinic Proc 1989; 64: 945-55.
56. Sugimachi K, Watanabe M, Sadanaga N, Ikebe M, Kitamura K, Mori M, Kuwano H. Recent advances in the diagnosis and surgical treatment of patients with carcinoma of the esophagus. J Am Coll Surg 1994; 178: 363-68.
57. Jamieson GG, Mathew G, Ludemann R, Wayman J, Myers JC, Devitt PG. Postoperative mortality following oesophagectomy and problems in reporting its rate. Br J Surg 2004; 91: 943-47.
58. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam Jr JB, Ajani JA et al. Treatment outcomes of resected esophageal cancer. Ann Surg 2002; 236: 376-85.
59. Dexter SPL, Sue-Ling H, McMahon MJ, Quirke P, Mapstone N, Martin IG. Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut 2001; 48: 667-70.
60. Moran G, Iyer H, Bailey A, Butterworth R. The 2005 cancer waiting times target: will we ever hit the target for oesophagogastric cancer? Gut 2005; 54 (Suppl 11): A28.
61. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without neoadjuvant chemotherapy in oesophageal cancer: a randomised control trial. Lancet 2002; 359: 1727-33.
62. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-67.
63. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80: 269-72.
64. Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992;127:1446-50.
65. Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A, Mantyla M, Modig H, Munck-Wikland E, Rosengren B, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16: 1104-9.
66. Maipang T, Vasinanukorn P, Petpichetchian C, Chamroonkul S, Geater A, Chansawwaang S, Kuapanich R, Panjapiyakul C, Watanaarepornchai S, Punperk S. Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 1994; 56: 191-97.
67. Baba M, Natsugoe S, Shimada M, Nakano S, Shirao K, Kusano C, Fukumoto T, Aikou T. Does preoperative chemotherapy cause adverse effects on the perioperative course of patients undergoing esophagectomy for carcinoma? Jpn J Thorac Cardiovasc Surg 1999; 47:199-203.
68. Kok TC, van Lanschot J, Siersema PD, van Overhagen H, Tilanus HW for the Rotterdam Esophageal Tumour Study Group. Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a phase III multicenter randomised controlled trial [Abstract]. Proc Am Soc Clin Oncol 1997; 16: 277 (abstract).
69. Brucher BL, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R, Dittler HJ, Molls M, Fink U, Siewert JR. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 2004; 30: 963-71.
70. Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I, Walpole ET, Thomson DB, Harvey JA, Smithers BM. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 2004; 91: 199-204.
71. Blazeby JM, Farndon JR, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 2000; 88: 1781-87.
72. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001; 88: 338-56.
73. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies. Eur J Cancer 1998. 34: 503-9.
74. Steyn RS, Grenier I, Darnton SJ, Cullen MH, Matthews HR. Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma. Clin Oncol (R Coll Radiol) 1995; 7: 382-84.
75. Giovannini M, Seitz JF, Thomas P, Hannoun-Levy JM, Perrier H, Resbaut M et al. Endoscopic ultrasonography for assessment of the response to combined radiation and chemotherapy in patients with esophageal cancer. Endoscopy 1997; 29; 4-9.
76. Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE. Concurrent radiation therapy and chemotherapy followed by esophgectomy for localised esophageal carcinoma. J Clin Oncol 1996. 14: 156-63.
77. Poplin E, Fleming T, Leichman L, Seydel HG, Steiger Z, Taylor S et al. Combined therapies for squamous cell carcinoma of the oesophagus, a Southwest Oncology Group Study. J Clin Oncol 1987; 5: 622-28.
78. Jones DR, Detterbeck FC, Egan TM, Parkewr L, Bernard SA, Tepper JE. Induction chemoradiotherapy followed by oesophagectomy in patients with carcinoma of the esophagus. Ann Thorac Surg 1997; 64: 185-92.
79. World Health Organisation. WHO handbook for reporting results of cancer treatment. 1979; publication no. 48. Geneva: WHO.
80. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
81. Ilson DH. Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? J Clin Oncol 2002; 20: 1962-64.
82. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
83. Laterza E, de Manzoni G, Guglielmi A, Rodella L, Tedesco P, Cordiano C. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 1999; 67: 1466-69.
84. Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000; 66: 827-31.
85. Zuccaro G Jr, Rice TW, Goldblum J, Medendorp SV, Becker M, Pimentel R, Gitlin L, Adelstein DJ. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999; 94: 906-12.
86. Isenberg G, Chak A, Canto MI, Levitan N, Clayman J, Pollack BJ, Sivak MV Jr. Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc 1998; 48: 158-63.
87. Chak A, Canto MI, Cooper GS, Isenberg G, Willis J, Levitan N, Clayman J, Forastiere A, Heath E, Sivak MV Jr. Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 2000; 88:1788-95.
88. Willis J, Cooper GS, Isenberg G, Sivak MV Jr, Levitan N, Clayman J, Chak A. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 2002; 55: 655-61.
89. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M, Park KG. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998; 85: 1403-6.
90. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001; 233: 300-9.
91. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A, Mortelmans L. Positron emission tomography for assessment of the response to induction radio chemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13: 361-68.
92. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002; 4:301-10.
93. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N, Endo K. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002; 184: 279-83.
94. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, Rusch V. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21: 428-32.
95. Kroep JR, Van Groeningen CJ, Cuesta MA, Craanen ME, Hoekstra OS, Comans EF, Bloemena E, Hoekstra CJ, Golding RP, Twisk JW, Peters GJ, Pinedo HM, Lammertsma AA. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol 2003; 5:337-46.
96. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004; 101: 1776-85.
97. Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 476-86.
98. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995; 221: 677-83.
99. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 2004; 239: 491-500.
100. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TP. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994; 74: 1693-98.
101. Shimada Y, Watanabe G, Yamasaki S, Maeda M, Kawabe A, Kaganoi JI, Itami A, Fukumoto M, Kanda Y, Imamura M. Histological response of cisplatin predicts patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer 2000; 36: 987-93.
102. Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998; 4: 2991-97.
103. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seeber S, Gabbert HE. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer 1999; 84: 86-91.
104. Quillien V, Raoul JL, Laurent JF, Meunier B, Le Prise E. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma. Oncol Rep 1998; 5: 1561-65.
105. Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S. CYFRA 21-1as a tumour marker for squamous cell carcinoma of the esophagus. Dis Esophagus 1998; 11: 35-39.
106. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 2004; 15: 1773-81.
107. Ajani JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004; 100: 2347-54.
108. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003; 89: 630-33.
109. Slater S, Shamash J, Wilson P, Gallagher CJ, Slevin ML. Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. Br J Cancer 2002; 87: 850-53.
110. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94: 641-46.
111. Conroy T, Etienne PL, Adenis A, Ducreux M, Paillot B, Oliveira J, Seitz JF, Francois E, Van Cutsem E, Wagener DJ, Kohser F, Daamen S, Praet M, Gorlia T, Baron B, Wils J; European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol 2002; 13: 721-29.
112. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB 3rd. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13: 87-93.
113. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 2002; 20: 2844-50.
114. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69.
115. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-79.
116. Larson SM, Schoder H, Yeung H. Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer. Cancer J 2004; 10: 243-50.
117. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 2004; 45: 56-68.
118. Cunningham D, Allum WH, Stenning SP, Weeden S, for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). ASCO Meeting Abstracts 2005: A4001.